Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Todd Goodman

Physician Assistant New City, NY Physician Assistant

NPI 1538649579 CMS profile 10433627

301 N Main St Ste 3, New City, NY 10956

Open in the dashboard

General payments

$6,346

345 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Todd Goodman of New City, NY is reported in the CMS Open Payments database as having received $6,346 across 345 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,596 75
2022 General $3,618 194
2021 General $1,132 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Todd Goodman
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Todd Goodman were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Todd Goodman Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,132 $132 $37–$438 $132
2022 $3,618 $155 $48–$522 $149
2023 $1,596 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. AbbVie, Inc. $1,058 56 payments
  2. Incyte Corporation $831 37 payments
  3. Janssen Biotech, Inc. $730 49 payments
  4. Novartis Pharmaceuticals Corporation $631 40 payments
  5. Genzyme Corporation $542 22 payments
  6. Regeneron Healthcare Solutions, Inc. $464 20 payments
  7. Pfizer Inc. $406 25 payments
  8. Amgen Inc. $339 18 payments
  9. LEO Pharma Inc. $291 25 payments
  10. Sun Pharmaceutical Industries Inc. $230 9 payments
  11. Other $825 44 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $6,135 342 payments
  2. Education $210 3 payments
Products named General payments · program years 2021–2023
  1. DUPIXENT Immunology $787 31 payments
  2. OPZELURA $746 36 payments
  3. RINVOQ $574 24 payments
  4. TREMFYA $553 25 payments
  5. DUPIXENT Inflammation And Immunology $441 19 payments
  6. COSENTYX $418 29 payments
  7. EUCRISA $372 24 payments
  8. SKYRIZI $357 25 payments
  9. Otezla $339 18 payments
  10. CIBINQO $247 14 payments
  11. Other $2,731 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

345 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record